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1. Introduction  
Research projects in life sciences aim at studying and better understanding biological 
systems. Over the past 50 years, tremendous advances in molecular biology and 
biochemistry have provided essential tools to dissect biological processes down to the 
molecular level. Most of the time, when studying the structure and function of proteins, 
obtaining sufficient quantities of the native form of the protein isolated from the relevant 
cells or tissue is not feasible. The development of recombinant DNA technologies to clone 
and express genes encoding proteins of interest has revolutionized the design and execution 
of research projects (Cohen et al., 1973). Indeed, access to purified recombinant proteins 
enables a wide spectrum of studies, ranging from structural characterization of protein-
protein- and protein-nucleic acid interactions to immunization programs to generate 
antibodies as research tools. The availability of sufficient quantities of purified recombinant 
proteins is often key to success. Furthermore, recombinant approaches for the production of 
proteins have profoundly impacted biomedical research and drug development as they 
have opened the possibility of producing clinical grade proteins as drugs. This has 
subsequently paved the way for the emergence and fast development of protein biologics 
that today represent a very successful and quickly expanding class of drugs (Saladin et al., 
2009; Chiverton et al., 2010).  
A variety of expression systems using prokaryotic and eukaryotic cells as well as in vitro 
translation systems can, in principle, be envisaged for any protein of interest. However, 
when the folding and the extent of post-translational modifications of the recombinant 
protein are critical, the use of a system that best maintains the characteristics of the native 
protein is preferential. In the context of drug development programs, the biological activity 
of the protein is of paramount importance. Eukaryotic expression systems, and in particular 
the use of mammalian host cells, is therefore attractive for the production of human 
recombinant proteins considered either as therapeutics or therapeutic targets (Andersen et 
al., 2002). In addition, different forms of a given protein, such as truncations, protein fusions 
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or modifications obtained via site-directed mutagenesis, are often needed in the course of a 
project and thus require the expression and purification of many protein variants in short 
periods of time. Therefore, the flexibility and speed of a particular system have also to be 
taken into consideration. Ideally, an expression system should combine high yield, ease of 
purification, high product quality and short timelines.  
In this chapter, we describe the design and use of multicistronic episomal protein expression 
vectors combined with improved cell culture methods and single step affinity purification in 
order to meet these requirements. This approach is rapid (4-6 weeks) and can be used in any 
laboratory equipped for mammalian cell culture and standard protein purification for the 
production, in the milligram per liter range, of biologically active recombinant proteins from 
cell culture supernatants.  
2. Approaches for recombinant protein expression in mammalian cells 
When studying human or mammalian proteins, expression in mammalian cells not only 
provides the optimal machinery for proper folding and post-translational modifications, but 
also facilitates the expression of large and multimeric protein complexes. Several 
approaches for recombinant protein expression in mammalian cells can be envisaged that 
dramatically differ in overall yield, workload and timelines (Colosimo et al., 2000). Small-
scale transient transfections offer a fast and flexible approach for producing microgram 
quantities of proteins in a short period of time (days). Different methods have been 
described for the delivery of plasmid DNA into cells that drives the transient expression of 
the gene of interest. Up-scaling this approach is feasible in order to produce larger amounts 
of proteins (milligrams to grams) in a short time. However large-scale transient expression 
requires significant quantities of both exponentially growing cells and DNA, as well as 
specialized equipment and is thus not easy to implement in all laboratories (Geisse et al., 
2005; Backliwal et al., 2008). Using transient approaches, a new transfection has to be 
performed for each protein production batch. 
The most commonly used strategy for large-scale protein expression (milligram to kilogram 
scale) is the establishment of stable cell lines, in which the expression plasmid incorporates 
into the host cell genome (Hacker et al., 2009). The plasmid also includes a marker that 
allows the selection and clonal amplification of cells that have stably integrated the 
expression plasmid (Costa et al., 2010). Once the genetic stability of the cell line has been 
established, it can be expanded, cryopreserved and used for multiple production runs thus 
maximizing batch to batch consistency of the expressed protein. The main limitation is that 
stable cell line generation is time-consuming and laborious. It is therefore well suited for the 
production of proteins at industrial scale or for the production of therapeutic proteins, but 
not for covering the evolving needs of a research project. 
Semi-stable expression offers a compromise between transient transfection and stable 
cell line generation. In this case, following transfection with a plasmid containing a 
selectable marker, pools of cells are expanded under selective pressure to obtain large 
volumes of cells expressing the protein of interest in a relatively short time (weeks). The 
main advantages and limitations of the methods described above are summarized in 
Table 1. 
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Approach Advantages Limitations 
Transient transfection
Small scale 
Fast (days) 
Small amounts of DNA and cells 
required 
Reduced yields 
(micrograms) 
Increased variability 
between batches 
Transient transfection
Large scale 
Fast (days) 
Intermediate yields (milligrams to 
grams) 
Large amounts of DNA and 
cells required 
Specialized equipment 
required 
Semi stable pools Relatively fast (weeks) 
Small amounts of DNA and cells 
required 
Intermediate yields (milligrams to 
grams) 
Single pool can be used for several 
production runs 
Heterogeneous cell 
population 
 
Stable cell lines Homogenous cell population 
High yields (grams to kilograms) 
Unlimited number of production runs
Increased product consistency 
Time consuming (months) 
Labour intensive cell line 
screening and 
characterization 
Table 1. Characteristics of different mammalian cell expression systems. 
3. Expression vector design 
3.1 Episomal vectors 
The generation and amplification of semi-stable cell pools is performed under selective 
pressure, for instance using an antibiotic resistance gene (Lufino et al. 2008; Wong et al. 
2009). After transfection, cells that have integrated plasmid DNA into their genome in a 
location that enables expression of the selectable marker will grow and expand. Depending 
on the genome integration site, the expression level of the selection marker and the gene of 
interest can vary significantly. Episomal vectors present the advantage that they can 
replicate and propagate extrachromosomally in the transfected cells without the need for 
genomic integration. Episomal vectors contain sequences from DNA viruses, such as bovine 
papilloma virus 1, BK virus or Epstein-Barr virus. The expression of viral early genes in the 
host cell such as the Epstein-Barr virus nuclear antigen 1 (EBNA-1) activates the viral origin 
of replication that is present in the vector, allowing its independent replication. This leads to 
an efficient retention of multiple copies of the plasmid expressing the gene of interest 
despite a non-equal partitioning between the dividing cells (Van Craenenbroeck et al., 2000). 
This high retention rate combined with the selective pressure ensures that expanded cells 
contain the expression construct. In addition, the high plasmid copy number leads to 
amplification of the gene of interest and higher protein expression similar to transient 
transfection experiments (Mazda et al., 1997). Here we focus on the use of the pEAK8 vector 
that encodes the puromycin resistance gene as a selection marker, the Epstein-Barr virus 
nuclear antigen 1 (EBNA-1) and the oriP origin of replication (Magistrelli et al., 2010). 
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3.2 Multicistronic expression vectors 
Vectors that can drive multiple gene expression have several advantages. Firstly, they can be 
used for the production of multimeric protein complexes resulting from the assembly of 
different polypeptides. Such protein complexes are frequently found in nature and their 
structural and functional properties can differ from those of their individual subunits. A series 
of single and dual promoter vectors was generated, based on the pEAK8 episomal vector 
described above (Figure 1). These vectors incorporated a multicistronic design enabling the co-
expression of 2 to 4 independent genes in addition to the antibiotic resistance genes and viral 
elements of the original episomal vector. The genes encoding the protein of interest can be 
cloned downstream of the EF1 or SR promoters that drive strong gene transcription. One or 
two subsequent internal ribosome entry sites (IRES) drive the translation of the second and 
third genes (Komar et al., 2005). The gene located after the first IRES is BirA and encodes a 
biotin ligase that can add a biotin molecule to a protein fused to the biotin acceptor peptide 
AviTag™ (Tirat et al., 2006). In all the vectors described here, enhanced green fluorescent 
protein (EGFP) was placed after the last IRES. In a multicistronic transcript, the last cistron is in 
principle the least translated. Thus, EGFP expression can be used as a reporter to indicate 
whether the genes of interest are also expressed, although it has to be noted that there is not 
necessarily a correlation between the expression levels of the protein of interest and EGFP.  
In this chapter, we focus on the expression of extracellular proteins or protein complexes. 
Their secretion into the culture medium is mediated by a leader sequence that can be either 
the original leader sequence of the protein to be expressed or a generic one. We successfully 
used the CD33 and Gaussia P. leader sequences for a variety of proteins (Magistrelli et al., 
2010). However, significantly different yields can be observed depending on the choice of 
leader sequence and this parameter should therefore be considered in order to optimize 
expression levels that are not satisfactory. When biotinylation of the secreted protein is 
desired, the biotin ligase must also be secreted so that it can add a biotin to the AviTag™ 
either during the secretion process or in the extracellular milieu. It is therefore mandatory to 
add a leader sequence to the BirA gene in order to obtain a biotinylated product. 
 
GOI, gene of interest; EF1, EF1 promoter; SR, SR promoter; IRES, internal ribosome entry site; BirA, 
biotin ligase; EGFP, enhanced green fluorescent protein; Tag, peptidic tag (His, AviTag™, HA, Flag or 
StrepTag). 
Fig. 1. Single promoter and dual promoter multicistronic vector design. 
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4. Generation of semi-stable cell pools 
4.1 Transfection and selection 
After molecular cloning of the gene - or genes - of interest in one of the vectors described 
above, the constructs can be verified by DNA sequencing. The plasmids are then transfected 
into mammalian cells using a liposome-based transfection reagent such as TransIT-LT1 
(Mirus, Madison, WI). The transfection step requires only small quantities of DNA and cells, 
typically 2x105 cells and 2 μg of plasmid DNA per well and the transfection is carried out in 
a 6-well plate. Although different mammalian cell lines can be used, in the examples given 
below, transformed human embryo kidney monolayer epithelial cells (PEAK cells) were 
transfected. These cells stably express the EBNA-1 gene, further supporting the episomal 
replication process, are semi-adherent and can be grown under standard conditions in a cell 
culture incubator (5% CO2; 37 °C in DMEM medium supplemented with 10% fetal calf 
serum). After 24h, cells were placed under selective conditions by adding medium 
containing 0.5–2 μg/mL puromycin, as cells harbouring the episomal vector are resistant to 
this antibiotic. 48h after transfection, its efficiency can be evaluated via the brightness of the 
EGFP signal as well as the proportion of EGFP positive cells in the wells, using 
epifluorescence microscopy.  
4.2 Amplification and production 
Cells are maintained in a serum-containing medium, which allows for fast growth, high 
viability and fast expansion without adaptation to serum-free medium. The selection and 
amplification process of the pool can easily be monitored by the increase in EGFP signal 
either using epifluorescence microscopy or flow cytometry (Figure 2).  
 
Fig. 2. EGFP expression in transfected pools of PEAK cells after 2 weeks of selection and 
propagation, monitored by epifluorescence microscopy (left) or flow cytometry (right).  
At this stage the expression of the protein of interest can be tested by ELISA or western blot 
analysis of the supernatant. This early evaluation point at the beginning of the selection 
process is not absolutely required but provides an indication that the protein can be 
expressed and secreted in this system. After one week, the cells are transferred to larger 
vessels and kept under selective pressure in order to expand the transfected cell population. 
Two to three weeks after transfection, cells can be used to seed Tri-flasks (Nunc) or 
disposable CELLine bioreactors (Integra) for the production step (Figure 3). Tri-flasks are 
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cell culture vessels that contain three levels for cells to adhere and thus maximize cell 
density in a limited space. The CELLine is a two compartment bioreactor that can be used in 
a standard cell culture incubator. The smaller compartment (15 mL) contains the cells and is 
separated from a larger (one liter) medium-containing compartment by a semi-permeable 
membrane with a cut-off size of 10 kDa (Bruce et al., 2002; McDonald et al., 2005). This 
system allows for the diffusion of nutrients, gases and metabolic waste products, while 
retaining cells and secreted proteins in the smaller compartment. It is also possible to use 
serum-free medium in the cell compartment and complete medium in the larger 
compartment. This allows for the secretion of the protein of interest into serum-free 
medium, which facilitates the purification process by decreasing the amount of 
contaminants. As the medium and cell compartments can be accessed independently, 
medium can be replaced or complemented with fresh medium without losing cells or the 
protein of interest. It overcomes the limitations of standard cell culture containers and offers 
the advantage that the secreted protein remains concentrated in smaller volume facilitating 
downstream purification. Using both systems, the culture is maintained for 7–10 days before 
harvest of the supernatant. As the medium contains serum, the cells maintain high viability 
and several production runs can be generated using the same cells and containers. 
 
Fig. 3. Schematic representation and timelines of the overall process.  
5. Protein purification 
In order to streamline the overall process, an important objective is to efficiently purify the 
secreted recombinant proteins with a single immobilized metal ion affinity chromatography 
step (IMAC). This affinity purification approach is well established for proteins containing a 
hexahistidine tag (Block et al., 2009). However, optimization was required to efficiently 
purify recombinant protein from supernatants containing 10% FCS. After harvest, the cell 
culture supernatants are clarified by centrifugation and filtered through a 0.22 μm 
membrane. The supernatant from Tri-flasks or other standard cell culture vessels have to be 
concentrated 20–40 times using a concentration device such as a SartoFlow 200 (Sartorius) 
with a membrane having an appropriate cut-off size to retain the protein of interest. As 
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mentioned above, this step is not required using the CELLine bioreactor due to the low 
volume recovered from the cell compartment. In addition, the concentration step increases 
the concentration of both the protein of interest and high molecular weight contaminants 
such as bovine serum albumin or immunoglobulins. In contrast, the supernatant retrieved 
from the cell compartment of the CELLine bioreactor contains concentrated recombinant 
protein and reduced levels of contaminants as they cannot cross the 10 kDa membrane 
separating the two chambers of the reactor. This increased recombinant protein to 
contaminant ratio greatly enhances the purification efficiency by IMAC. The concentrated 
supernatant is then supplemented with 100 mM imidazole and loaded onto Ni–NTA affinity 
chromatography resin (Qiagen). The relatively high concentration of imidazole minimizes 
binding of contaminants to the resin. After a wash step, proteins are eluted at a flow rate of 
2 mL/min using a 30 mL imidazole gradient (20–400 mM imidazole) on an ÄKTA Prime 
chromatography system (GE Healthcare). The elution gradient further improves the purity 
of the recombinant protein but can be replaced by a step elution approach if a 
chromatography system is not available. The eluted fractions can be analyzed by SDS-PAGE 
or ELISA to determine their recombinant protein content. The fractions of interest are 
pooled and desalted on PD-10 columns (GE Healthcare) equilibrated with phosphate 
buffered saline or another appropriate buffer. The desalted proteins can then be quantified 
using various techniques and their purity analyzed by SDS-PAGE. 
During the expansion step of the cell pools, several vials of cells can be cryopreserved in 
liquid nitrogen. These frozen pools can be thawed at a later stage and rapidly expanded 
under selective conditions to produce recombinant protein without the need for a new 
transfection step. This possibility further accelerates the timelines for the generation of 
additional recombinant protein batches and is a clear advantage over transient transfection 
approaches (Table 1). 
Protein Yield (mg/L) Tags 
Human IL-17F homodimer 5 - 6 His 
Human IL-17A homodimer 6 - 9 His - StrepTag 
Human IL-17A/F heterodimer 0.4 - 1 His - StrepTag 
Rat IL-17A homodimer 2 - 4 His - StrepTAg 
Human IL-6 11 - 14 His - AviTag™ 
Mouse IL-6 10 - 12 His - AviTag™ 
Human IL-6 receptor 15 - 16 His - AviTag™ 
Mouse IL-6 receptor 13 - 14 His - AviTag™ 
Human IL-6 / IL-6 receptor complex 7 - 9 His 
Human CD16b 7 - 8 His - AviTag™ 
Human CD79A homodimer 4 - 6 His - AviTag™ 
Human CD79B homodimer 0.5 - 1 His - AviTag™ 
Human CD79A/B heterodimer 0.8 - 1 His - AviTag™ 
Human LIF 5 - 6 His 
Mouse LIF 4 - 6 His 
Mouse FcγRIV 4 - 5 His - AviTag™ 
Table 2. Proteins successfully expressed using the process described in this chapter.  
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We have applied the process described above to express and purify 16 mammalian proteins 
(Table 2). In most cases, several milligrams of highly pure recombinant protein were 
obtained per liter of cell culture supernatant (Magistrelli et al., 2010). The proteins carried 
various tags at the N- or C-terminus and could be biotinylated in vivo during the 
production step via an AviTagTM. Most of these proteins were shown to be functionally 
active in cell-based assays. 
Three case studies are reported below, illustrating the expression, purification and 
characterization of monomeric, homodimeric and heterodimeric recombinant proteins. 
6. Case studies 
6.1 Monomeric proteins: Recombinant biotinylated human CD16b  
Human CD16b, also called FcRIIIb, is a member of the receptor family for the Fc of 
immunoglobulins (Takai, 2002). CD16b is a low affinity, GPI-anchored, monomeric receptor 
expressed on neutrophils and eosinophils. In order to characterize the binding of human IgG 
to this receptor, a DNA fragment encoding the extracellular portion of hCD16b fused to a C-
terminal hexahistidine and an AviTagTM was cloned into the single promoter tricistronic vector 
that drives the co-expression of BirA and EGFP (Figure 1). After transfection and selection, 
hCD16b was purified in a single step from the cell culture supernatant as described above. The 
elution fractions corresponding to the main elution peak of the chromatogram were pooled 
and desalted into phosphate buffered saline. SDS-PAGE analysis showed that hCD16b was 
highly pure and had the expected molecular weight of 43 kDa (Figure 4).  
In order to verify that hCD16b was biotinylated during expression, an aliquot of each 
pooled fraction was added to streptavidin coated microplates. After incubation, the plate 
was washed and the immobilized hCD16b detected using a horseradish peroxydase (HRP)-
coupled anti-hexahistidine antibody (Figure 5). The ELISA signals correlated with the 
intensity of the bands on the SDS-PAGE gel and indicated that hCD16b was efficiently 
biotinylated, thus facilitating its immobilization on a solid surface.  
 
Fig. 4. Purification of hCD16. Chromatogram of the gradient elution step (left). The indicated 
fractions were collected in several pools, desalted and analyzed by SDS-PAGE (right). 
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The ability of purified hCD16b to bind IgG was tested by Surface Plasmon Resonance (SPR) 
using a Biacore 2000 instrument (GE Healthcare). A CM5 biosensor chip was coated with 
streptavidin followed by injection of hCD16b, resulting in efficient immobilization of the 
receptor on the chip surface. Kinetic experiments were performed by injecting various 
concentrations of hIgG1, ranging from 83 nM to 1.3 μM (Figure 5). Dose dependent binding 
was observed and the affinity of the interaction could be determined (KD=7.18x10-5 ± 3.2 
x10-5 M). The affinity of human IgG1 for hCD16b was found to be similar to previously 
described values (Bruhns et al., 2009). 
 
 
 
 
 
Fig. 5. Characterization of hCD16b by ELISA (left) and by Surface Plasmon Resonance on a 
Biacore 2000 system (right). Pooled fractions of purified hCD16b were captured on a 
streptavidin-coated ELISA plate and detected with and anti-hexahistidine antibody (left). 
The sensorgrams were obtained by injecting hIgG1 on hCD16b immobilized on a 
streptavidin surface (right). A schematic representation of the IgG-CD16b interaction on the 
chip surface is represented in the top right corner. 
6.2 Homodimeric proteins: Recombinant human IL-17F 
Interleukin 17F (IL-17F) is a member of the IL-17 cytokine family and has been shown to 
play a pro-inflammatory role, particularly in asthma (Kawaguchi et al., 2009). IL-17F is a 
secreted protein that forms a homodimer linked by a disulfide bond (Hymowitz et al., 2001). 
This protein was expressed using the single promoter bicistronic variant of the vector 
(Figure 1). The transfection, selection and purification process described above was applied 
and the purity of dimeric IL-17F was confirmed by denaturing SDS-PAGE in reducing and 
non-reducing conditions (Figure 6). As expected the IL-17F monomer and disulphide-linked 
dimer had an apparent molecular weight of 20 kDa and 40 kDa, respectively. 
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Fig. 6. Purification of human IL-17F homodimer. Chromatogram of the gradient elution step 
(top). The indicated fractions were collected in several pools, desalted and analyzed by SDS-
PAGE in non-reducing conditions (bottom left) and in reducing conditions (bottom right). 
The biological activity of purified hIL-17F was assessed in a cell-based assay (Yao et al., 
1995). Human fibroblasts secrete IL-6 in response to hIL-17F and this activity can be 
inhibited by a neutralizing antibody directed against hIL-17F. The neutralizing activity of 
the antibody was tested in the assay using hIL-17F purified from the supernatant or a 
commercial source of the cytokine (PeproTech). The results indicated that both cytokines 
have equivalent biological activities and can be neutralized in a similar fashion by the 
antibody (Figure 7).  
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Fig. 7. Neutralization of the biological activity of commercially available hIL-17F (closed 
circles) and purified hIL-17F (open circles) using an anti-hIL-17F monoclonal antibody (left). 
Schematic representation of the cell-based assay (right).  
6.3 Heterodimeric proteins: Recombinant human CD79A/B 
As an example demonstrating successful heterodimeric protein complex expression, the 
sequences encoding the extracellular domains of human CD79A and CD79B were cloned 
into a dual promoter, tricistronic vector (Figure 1). The native CD79A/B heterodimer is 
expressed on B lymphocytes and is the signalling component of the B cell receptor complex 
(Chu et al., 2001). For recombinant expression, the two proteins were fused to different tags. 
A hexahistidine tag was introduced at the C-terminus of CD79B for purification by IMAC 
and an AviTag™ at the C-terminus of CD79A for in vivo biotinylation. During the 
purification step, CD79A/B heterodimer and CD79B homodimer complexes were purified 
via the hexahistidine tag on CD79B. The purified protein complexes analyzed by SDS-PAGE 
presented a diffuse pattern due to glycosylation of the proteins (Figure 8). As only CD79A is 
biotinylated, only the heterodimeric complex can be specifically immobilized on 
streptavidin coated surfaces.  
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Fig. 8. Purification of human CD79A/B heterodimer. Chromatogram of the gradient elution 
step (left). The indicated fractions were collected in several pools, desalted and analyzed by 
SDS-PAGE (right). 
 
Fig. 9. Schematic representation of the ELISA used for the detection of CD79A/B 
heterodimer in the pooled elution fractions (top). ELISA signals obtained using anti-CD79A 
(bottom left) and anti-hCD79B (bottom right) antibodies and dilutions of the pooled 
fractions (pools 2 to 5). Biotinylated hCD79A and hCD79B homodimers were used as 
positive and negative controls.  
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To confirm the presence of the CD79A/B heterodimer in the purified fractions, aliquots 
were incubated in streptavidin-coated ELISA plates. After washing, commercial anti-CD79A 
and anti-CD79B antibodies were added to different wells and detected using a HRP-labeled 
Fcγ specific antibody (Figure 9). Positive signals obtained with both anti-CD79A and anti-
CD79B antibodies demonstrated that the heterodimer was efficiently produced and 
captured via biotin-streptavidin interaction.  
7. Conclusions 
A number of considerations can influence the choice of system for the expression of 
recombinant proteins, but the final intended use of the protein is a key determining factor. 
For most applications, the recombinant protein should closely mimic the structural and 
functional properties of the native protein. For this reason, mammalian expression that 
provides the appropriate folding and complex post-translational and secretion machineries 
represents the system of choice for the study of human proteins, in particular for therapeutic 
applications (Andersen et al., 2002). High yields, flexibility and speed are also important 
parameters that are difficult to combine in a single and ideal expression system. Transient 
expression via plasmid transfection into mammalian cells provides maximal flexibility and 
speed, at the expense of yield. Indeed, only microgram amounts of protein can be obtained 
unless performed at large scale, a procedure that has its own technical challenges and is 
therefore not easily implemented in most laboratories (Hacker et al. 2009). At the other end 
of the spectrum, the establishment and selection of stable cell lines supporting high 
expression levels is time consuming but is clearly a system of choice when large amounts of 
protein are required. In addition, the clonal nature of the cell line increases product 
homogeneity and batch-to-batch consistency, two highly desirable features for industrial 
applications. However, neither approach is fully satisfactory when conducting research 
projects that involve the development of protein-protein interaction assays, structural 
characterization, immunization or screening procedures. Such activities require milligram 
amounts of protein and often multiple variants, fusions or tagged version of the same 
protein have to be generated.  
The expression system described in this chapter contributes to bridging the gap between 
yield and speed by providing several attractive features: integration-free maintenance of 
the expression vector via autonomous episomal replication; single or dual promoter 
multicistronic vector design for the co-expression of proteins; secretion of biotin ligase for 
single site in vivo protein biotinylation; co-expression of EGFP for the monitoring of 
transfection efficiency, selection and amplification of cell pools; cryopreservation of cell 
pools for additional batch productions; single step affinity purification and use of 
disposable bioreactors. The latter element, although not strictly required, significantly 
enhances the overall quality of the process by providing highly concentrated 
supernatants, containing lower levels of serum derived contaminants, thus improving the 
performance of the affinity chromatography step. This 4-6 weeks process requires 
standard cell culture and protein purification equipment and can therefore be 
implemented in most laboratories. Beyond speed and yield, the possibility to obtain single 
site biotinylated proteins facilitates the development of protein-protein interaction assays 
via simple biotin-streptavidin oriented immobilization of one of the interacting partners. 
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Finally, as illustrated by several examples, the mammalian cell machinery offers the 
possibility to produce homodimeric and heterodimeric protein complexes in significant 
quantities.  
In our laboratory, the availability of this approach has significantly simplified and 
streamlined the production of high quality recombinant proteins and supported multiple 
aspects of our research programs. We therefore believe that it could also benefit other 
research groups and become more widely used for the expression of recombinant 
proteins. 
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